Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore

Epilepsy Research

Volumn 108, Issue 7, 2014, Pages 1253-1262

  Kong, Sing Teang ^a   Ho, Choon Siang ^a   Ho, Paul C ^a   Lim, Shih Hui ^b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c National Neuroscience Institute   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Adults; Asian; Drug resistant epilepsy; Prevalence; Refractory epilepsy; Singapore

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLURRED VISION; BRAIN ATROPHY; CHILD; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE DURATION; DIZZINESS; DRUG RESISTANT EPILEPSY; DRUG RESPONSE; DYSPLASIA; ELECTROENCEPHALOGRAPHY; EPILEPSY; ETHNICITY; FEMALE; FOCAL EPILEPSY; GINGIVA DISEASE; HAIR LOSS; HIPPOCAMPAL SCLEROSIS; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DEFICIENCY; MENTAL DISEASE; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEUROIMAGING; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SINGAPORE; SOMNOLENCE; SPEECH DISORDER; TERTIARY CARE CENTER; TONIC CLONIC SEIZURE; UNIVARIATE ANALYSIS; VERY ELDERLY; WEIGHT GAIN; DRUG RESISTANCE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREVALENCE; SINGAPORE; TERTIARY CARE CENTERS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84904683310     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.05.005     Document Type: Article

References (39)

1. ATC/DDD Index 2013 World Health Organization Collaborating Centre for Drug Statistics Methodology 2012, Available from: http://www.whocc.no/atc_ddd_index/ (accessed 02.01.13).
2. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W., Engel J., French J., Glauser T.A., Mathern G.W., Moshe S.L., Nordli D., Plouin P., Scheffer I.E. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
3. Berg A.T., Shinnar S. Do seizures beget seizures? An assessment of the clinical evidence in humans. J. Clin. Neurophysiol. 1997, 14:102-110.
4. Berg A.T., Shinnar S., Levy S.R., Testa F.M., Smith-Rapaport S., Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 2001, 56:1445-1452.
5. Brodie M.J. Road to refractory epilepsy: the Glasgow story. Epilepsia 2013, 54(Suppl. 2):5-8.
6. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408. Levetiracetam Monotherapy Study Group.
7. Brodie M.J., Richens A., Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995, 345:476-479.
8. Callaghan B., Schlesinger M., Rodemer W., Pollard J., Hesdorffer D., Allen Hauser W., French J. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011, 52:619-626.
9. Chan D., Phuah H.K., Ng Y.L., Choong C.T., Lim K.W., Goh W.H. Pediatric epilepsy and first afebrile seizure in Singapore: epidemiology and investigation yield at presentation. J. Child Neurol. 2010, 25:1216-1222.
10. Engel J., McDermott M.P., Wiebe S., Langfitt J.T., Stern J.M., Dewar S., Sperling M.R., Gardiner I., Erba G., Fried I., Jacobs M., Vinters H.V., Mintzer S., Kieburtz K. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 2012, 307:922-930.
11. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught R.E., Sachdeo R.C., Beydoun A., Glauser T.A., American Academy of Neurology T, Technology Assessment S, American Academy of Neurology Quality Standards S, American Epilepsy Society T, Technology Assessment S, American Epilepsy Society Quality Standards S Efficacy and tolerability of the new antiepileptic drugs. II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:410-423.
12. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught R.E., Sachdeo R.C., Beydoun A., Glauser T.A., Therapeutics, Technology Assessment Subcommittee of the American Academy of N, Quality Standards Subcommittee of the American Academy of N, American Epilepsy S Efficacy and tolerability of the new antiepileptic drugs. I: Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1252-1260.
13. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., Kalviainen R., Mattson R., Perucca E., Tomson T. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
14. Goodridge D.M., Shorvon S.D. Epileptic seizures in a population of 6000. II: Treatment and prognosis. Br. Med. J. (Clin. Res. Ed.) 1983, 287:645-647.
15. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007, 75:192-196.
16. Hui A.C., Wong A., Wong H.C., Man B.L., Au-Yeung K.M., Wong K.S. Refractory epilepsy in a Chinese population. Clin. Neurol. Neurosurg. 2007, 109:672-675.
17. Kun L.N., Ling L.W., Wah Y.W., Lian T.T. Epidemiologic study of epilepsy in young Singaporean men. Epilepsia 1999, 40:1384-1387.
18. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., Moshe S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
19. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
20. Lim S.-H., Tan E.-K., Chen C. Pattern of antiepileptic drug usage in a tertiary referral hospital in Singapore. Neurol. J. Southeast Asia 1997, 2:77-85.
21. Loh N.K., Lee W.L., Yew W.W., Tjia T.L. Refractory seizures in a young army cohort. Ann. Acad. Med. Singapore 1997, 26:471-474.
22. Luoni C., Bisulli F., Canevini M.P., De Sarro G., Fattore C., Galimberti C.A., Gatti G., La Neve A., Muscas G., Specchio L.M., Striano S., Perucca E., Group S.S. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011, 52:2181-2191.
23. Lwanga S.K., Lemeshow S. Sample Size Determination in Health Studies: A Practical Manual 1991, World Health Organization, Geneva.
24. MacDonald B.K., Johnson A.L., Goodridge D.M., Cockerell O.C., Sander J.W., Shorvon S.D. Factors predicting prognosis of epilepsy after presentation with seizures. Ann. Neurol. 2000, 48:833-841.
25. Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick D.W., Cramp C., Cockerell O.C., Cooper P.N., Doughty J., Eaton B., Gamble C., Goulding P.J., Howell S.J., Hughes A., Jackson M., Jacoby A., Kellett M., Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith D.F., Smith P.E., Smith C.T., Vanoli A., Williamson P.R., group S.S. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
26. Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick D.W., Cramp C., Cockerell O.C., Cooper P.N., Doughty J., Eaton B., Gamble C., Goulding P.J., Howell S.J., Hughes A., Jackson M., Jacoby A., Kellett M., Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith D.F., Smith P.E., Smith C.T., Vanoli A., Williamson P.R., group S.S. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
27. Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N. Engl. J. Med. 1992, 327:765-771.
28. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., Williamson P.D., Treiman D.M., McNamara J.O., McCutchen C.B., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985, 313:145-151.
29. Miller J.W. Are we too pessimistic about drug-resistant epilepsy?. Epilepsy Curr. 2012, 12:232-233.
30. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. 2006, 13:277-282.
31. Picot M.C., Baldy-Moulinier M., Daures J.P., Dujols P., Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008, 49:1230-1238.
32. Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch. Neurol. 2009, 66:1233-1239.
33. Schmidt D., Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol. Scand. 2005, 111:291-300.
34. Sillanpaa M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993, 34:930-936.
35. Sillanpaa M., Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006, 129:617-624.
36. Stephen L.J., Kelly K., Mohanraj R., Brodie M.J. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav. 2006, 8:434-437.
37. Stephen L.J., Kwan P., Brodie M.J. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?. Epilepsia 2001, 42:357-362.
38. Taylor R.S., Sander J.W., Taylor R.J., Baker G.A. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011, 52:2168-2180.
39. Vahab S.A., Sen S., Ravindran N., Mony S., Mathew A., Vijayan N., Nayak G., Bhaskaranand N., Banerjee M., Satyamoorthy K. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab. Pharmacokinet. 2009, 24:255-260.